Abiomed Stock Soars After $16.6 Billion Johnson & Johnson Takeover Amid Deeper Medical Devices Push
"The addition of Abiomed is an important step in our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech," said CEO Joaquin Duato.
Tuesday, November 1, 2022 at 12:45 pm